Propanc Biopharma (NASDAQ: PPCB) is pursuing a strategic acquisition plan focused on undervalued digital asset management (DAT) companies. According to PANews, Propanc aims to acquire these firms at a discount to their market-to-net asset value (MNAV), seeking to bolster its balance sheet, diversify its assets, and create long-term value for shareholders. These DAT companies typically hold substantial amounts of popular cryptocurrencies like Bitcoin and Ethereum on their balance sheets. Propanc’s board and executive team are currently conducting due diligence on potential targets, carefully evaluating the firms’ financial strength, digital asset holdings, and operational compatibility.